The prevalence of symptomatic benign prostatic hypertrophy (BPH) in Europe varies from 14% for men in their fourth decade to more than 40% in their sixth. Assuming an overall prevalence of symptomatic BPH of 30%, in the UK, would mean that approximately 4 million men aged more than 40 years suffer from the condition.
BaldwinK.C.GinsbergP.C.RoehrbornC.G.HarkawayR.C.Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology (2001) 58(2): p. 203–9
3.
BarkinJ.GuimaraesM.JacobiG.Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. European Urology (2003) 44(4): p. 461–6
4.
BarryM.J.FowlerF.J.O'LearyM.P.The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology (1992) 148(5): p. 1549–57
5.
BentS.KaneC.ShinoharaK.Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine (2006) 354(6): p. 557–66
CrawfordE.D.Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU International (2005) 95(suppl 4) 1–5
8.
De la RosetteJ.MadersbacherS.AlivizatosG.Guidelines on benign prostatic hyperplasia. European Association of Urology (2004)
9.
DjavanB.MarbergerM.A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology (1999) 36(1): p. 1–13
10.
EdwardsJ.E.MooreR.A.Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urology (2002) 2(1): p. 14
11.
EkmanP.Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. European Urology (1998) 33(3): p. 312–7
12.
EngstromG.Walker-EngstromM.L.HenningsohnL.Prevalence of distress and symptom severity from the lower urinary tract in men: a population-based study with the DAN-PSS questionnaire. Family Practice (2004) 21(6): p. 617–22
13.
IshaniA.MacDonaldR.NelsonD.Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. American Journal of Medicine (2000) 109(8): p. 654–64
14.
KaplanS.A.VolpeM.A.TeA.E.A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. Journal of Urology (2004) 171(1): p. 284–8
15.
KlimbergI.W.LockeD.R.LeonardE.Outpatient transurethral resection of the prostate at a urological ambulatory surgery center. Journal of Urology (1994) 151(6): p. 1547–9
16.
LeporH.WillifordW.O.BarryM.J.The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New England Journal of Medicine (1996) 335(8): p. 533–9
17.
LoweF.C.Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU International (2005) 95(suppl 4) 12–8
18.
MadersbacherS.AlivizatosG.NordlingJ.EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). European Urology (2004) 46(5): p. 547–54
19.
McConnellJ.D.RoehrbornC.G.BautistaO.M.The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine (2003) 349(25): p. 2387–98
NICE. Transurethral electrovaporisation of the prostate. Interventional procedure guidance 14 (2003a) National Institute for Health and Clinical Excellence. Accessedviawww.nice.org.uk/nicemedia/pdf/ip/IPG014guidance.pdf [date last accessed 10.08.2008]
25.
NICE. Transurethral radiofrequency needle ablation of prostate. Interventional procedure guidance 15 (2003b) National Institute for Health and Clinical Excellence. Accessed via www.nice.org.uk/nicemedia/pdf/ip/ipg015guidance.pdf [date last accessed 10.08.2008]
26.
NICE. Holmium laser prostatectomy. Interventional procedure guidance 17 (2003c) National Institute for Health and Clinical Excellence. Accessed via www.nice.org.uk/nicemedia/pdf/ip/ipg017guidance.pdf [date last accessed 10.08.2008]
27.
NICE. Potassium-titanyl-phosphate (KTP) laser vaporisation of the prostate for benign prostatic obstruction. Interventional procedure guidance 120 (2005a) National Institute for Health and Clinical Excellence. Accessed via www.nice.org.uk/nicemedia/pdf/ip/IPG120guidance.pdf [date last accessed 10.08.2008]
28.
NICE. Referral guidelines for suspected cancer: quick reference guide. Clinical guideline 27 (2005b) National Institute for Health and Clinical Excellence. Accessed via www.nice.org.uk/Guidance/CG27 [date last accessed 10.08.2008]
29.
NickelJ.C.ElhilaliM.VallancienG.ALF-ONE Study Group Benign prostatic hyperplasia (BPH) and pro statitis: prevalence of painful ejaculation in men with clinical BPH. BJU International (2005) 95(4): p. 571–4
SagalowskiA.L.WilsonJ.D.Hyperplasia and carcinoma of the prostate. In FauciA.S.LongoD. (eds) Harrison's principles of internal medicine14th edn (1998) New York: McGraw-Hill, 1–10
32.
SpeakmanM.J.KirbyR.S.JoyceA.Guideline for the primary care management of male lower urinary tract symptoms. BJU International (2004) 93(7): p. 985–90
33.
VallancienG.EmbertonM.HarvingN.Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. Journal of Urology (2003) 169(6): p. 2257–61
34.
WebberR.Benign prostatic hyperplasia. BMJ Clinical Evidence (2004) BMJ Publishing Group Ltd. Accessed via www.clinicalevidence.com [date last accessed 14.05.2008]
35.
WessellsH.RoyJ.BannowJ.Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology (2003) 61(3): p. 579–84
36.
WiltT.MacDonald R.IshaniA.Cernilton for benign prostatic hyperplasia (Cochrane Review). The Cochrane Library. (1998)Issue 3 John Wiley & Sons, Ltd. Accessed via www.thecochranelibrary.com [date last accessed 03.06.2008]
37.
WiltT.IshaniA.MacD.R.Beta-sitosterols for benign prostatic hyperplasia (Cochrane Review). The Cochrane Library. (1999)Issue 3 John Wiley & Sons, Ltd. Accessed via www.thecochranelibrary.com [date last accessed 03.06.2008]
38.
WiltT.J.IshaniA.RutksI.MacDonaldR.Phytotherapy for benign prostatic hyperplasia. Public Health Nutrition (2000) 3(4A): p. 459–72
39.
WiltT.J.MacDonald R.RutksI.Tamsulosin for benign prostatic hyperplasia (Cochrane Review). The Cochrane Library. (2002a)Issue 4 John Wiley & Sons, Ltd. Accessed via www.thecochranelibrary.com [date last accessed 03.06.2008]
40.
WiltT.IshaniA.MacDonald R.Serenoa repens for benign prostatic hyperplasia (Cochrane Review). The Cochrane Library. (2002b)Issue 3 John Wiley & Sons, Ltd. Accessed via www.thecochranelibrary.com [date last accessed 03/06/2008]
41.
WiltT.J.HoweW.MacDonaldR.Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU International (2002c) 89(3): p. 214–25
